Ann: 12 Distributors Signed for Remplir Covering 21 States in US, page-103

First 103 Last

Share
Profile

Follow
TBALL

896 Posts.

288

11/05/25

22:18

Post #: 78999799
Share

Originally posted by sabine: ↑

https://thewest.com.au/business/bio...rs-for-nerve-repair-device-remplir-c-18610307

Orthocell’s easy cell into the US as it secures 12 distributors for nerve repair device Remplir

Cheyanne EncisoThe West Australian
Sun, 11 May 2025 3:21PM

Orthocell chair John Van Der Wielen and chief Paul Anderson at its HQ in Murdoch. Credit: Danella Bevis/The West Australian

Orthocell says it has moved at “warp speed” to secure US distributors for its nerve repair device, marking another milestone in the WA biotech’s commercialisation push into the world’s biggest healthcare market.
Fresh from winning US Food and Drug Administration approval for Remplir, ASX-listed regenerative medicine company Orthocell has now appointed 12 nerve specialists as distributors.
Collectively, they have operations spanning 21 States in the US and will be tasked with marketing and distributing Remplir — a collagen nerve wrap used in the repair of peripheral nerve injuries as a result of motor vehicle, sporting or work-related injuries — to surgeons.

“It’s nearly $80 million to get to this stage of research and development . . . it’s a lot of money and a lot of time in over a decade,” Orthocell chair John Van Der Wielen said.
“It’s been a rough long road but we’ve now got the road, I would say, tarmacked. We’re on smooth driving and now the revenue and profit will come next.”
The FDA nod in April for Remplir unlocks the door to a lucrative nerve repair market worth $US1.6 billion ($2.5b).
It adds to Remplir’s string of regulatory approvals, including most recently in Thailand, Canada and Singapore. Regulatory applications for the EU and the UK are set to be submitted in the next few months.
Having made its first shipment into the US, Orthocell chief Paul Anderson reiterated there was no need to move the company’s manufacturing base out of its facility in Murdoch, despite Donald Trump’s 10 per cent baseline tariff on Australian goods.

“The challenges and the excitement that lays in front of us is in the American market,” Mr Anderson said.
“We are sovereign partners with the United States and the US does need to have manufacturing security in allies like Australia. We hold no fears with regards to the tariffs.”

Mr Van Der Wielen added it was highly unlikely US tariffs were targeting complex medical devices that patients need.
“(As an example) high volume eye drops made by a US company . . . now being manufactured in India or China is more of the target, not a sophisticated medical device that changes people’s lives,” he said.
Orthocell’s other flagship product Striate+ — designed to protect the bone defect from ingrowth of gingival, or gum, tissue — is also approved in several markets, including in Australia, Singapore, the US, Canada and Brazil.
Mr Van Der Wielen said while biotech investors were “absolutely” aware of Orthocell’s success story, there was more to do.
“Do I think Western Australians per se recognises (Orthocell) as somewhere they can go and become employed as a young scientist? Yes, more than it used to be . . . but we’ve got to get that story out to people a little bit better,” he said.
The company already employs 55 staff across its operations in Australia and the US. It plans to grow that number to 100 in the near-term as manufacturing ramps up.

Expand

Great News article over the weekend, this will stimulate research into OCC and will be reinforced when they announce Remplir approval in Hong Kong Monday morning.

OCC Price at posting: $1.38 Sentiment: Buy Disclosure: Held
12 Upvote

1 Great analysis

Reply

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

First 103 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.22		Change 0.015(1.24%)		Mkt cap ! $296.8M

Open	High	Low	Value	Volume
$1.20	$1.24	$1.20	$621.0K	510.8K

Buyers (Bids)

No.	Vol.	Price($)
1	3346	$1.22

Sellers (Offers)

Price($)	Vol.	No.
$1.23	5513	1

View Market Depth

No.	Vol.	Price($)
1	3346	1.220
2	10082	1.210
1	10000	1.205
18	190463	1.200
3	19162	1.195

Price($)	Vol.	No.
1.230	5513	1
1.235	23511	2
1.240	43034	4
1.245	16937	4
1.250	24000	3

Last trade - 16.10pm 17/06/2025 (20 minute delay)

OCC (ASX) Chart

Ann: 12 Distributors Signed for Remplir Covering 21 States in US, page-103

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 12 Distributors Signed for Remplir Covering 21 States in US, page-103

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News